Comparative Pharmacology
Head-to-head clinical analysis: GRANIX versus ZARXIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRANIX versus ZARXIO.
GRANIX vs ZARXIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Granix (tbo-filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) analog that binds to G-CSF receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
ZARXIO (filgrastim-sndz) is a recombinant human granulocyte colony-stimulating factor (G-CSF) that binds to specific cell surface receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
5 μg/kg subcutaneously once daily for up to 7 days, or 5 μg/kg subcutaneously once daily for up to 14 days for stem cell mobilization.
5 mcg/kg subcutaneously once daily. Round to nearest vial size (300 mcg/0.5 mL or 480 mcg/0.8 mL).
None Documented
None Documented
Terminal half-life approximately 3.5 hours (range 1.8–5.4 h) in healthy subjects; clearance increases with neutrophil recovery due to G-CSF receptor-mediated uptake.
Terminal elimination half-life is approximately 3.5-4.5 hours in healthy adults; prolonged in renal impairment (up to 40 hours in end-stage renal disease).
Primarily renal excretion; neutrophil-mediated clearance. <1% unchanged in urine.
Primarily renal (70-80% as unchanged drug) via glomerular filtration; biliary/fecal excretion is negligible (<5%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor